ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference
11 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference.
The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: